Beyond animal models, clinical studies have found that low-dose human-recombinant IL-2 treatment was safe in immunosuppressing patients with hepatitis C-induced vasculitis (HCV vasculitis) [20], chronic graft-versus-host disease (GvHD) [21] and SLE [22]. The gene discussed is IL2; the disease is systemic lupus erythematosus.